ELEVĒO
2.6.2020 16:02:12 CEST | Business Wire | Press release
ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd , 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/
For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry.
Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and innovative WFO products. We believe this is a direct result of our core purpose; to create great customer experiences and serve the needs of others: employees, partners & end users. The ZOOM International brand has served us well.
So, why change brands now? As with all strategic business initiatives, there are many reasons, but here are the most impactful:
- Our software platform strategy has culminated in a new native cloud foundation for our products, opening-up new services, products, pricing, and subscription models. With new, improved platform and product capabilities, we felt it deserved a fresh name and look.
- Moreover, we are dedicated to constant improvement. Our mission is to elevate every encounter, which directly focuses on elevating employee engagement, elevating the customer experience and of course increasing the efficiency of each and every channel interaction with a distinct focus on compliance.
The company we created 20 years ago is a very different company than we are today. We are adapting to new business and market needs, serving a broader audience, and migrating to a subscription & cloud native focused strategy.
Effective June 2nd, 2020 ZOOM International will begin solely doing business under the elevēo brand name. All ZOOM International manufactured software products, and solutions (including OEMs) will be developed, marketed, sold, and supported under the elevēo name. In addition to the name, we will be launching a new software as a service offering the week of August 17th, that we call elevēo as a service which allows customers to subscribe to elevēo products without the burden of hosting them and with lower upfront cost.
Perhaps the reasons are best said from our CEO Brian Shore: “We are delighted to announce our new name and brand – Eleveo! Eleveo is closely connected to the Latin word elevo which translates to lift up or to raise. When we think about our mission and how we genuinely wish to serve others. When we think about our products and solutions and the problems we solve. We felt Eleveo in one word universally defines our brand, our culture and our passion to serve others!”
While our name has changed, our culture will not! Serving the needs of others and elevating every encounter is our brand promise! We will continue to innovate, offer greater flexibility, and do business your way as elevēo.
ABOUT ZOOM International
ZOOM guides contact centers toward increased revenue and decreased customer attrition by elevating every customer encounter. Our software captures customer sentiment, providing a true north to guide contact centers in the measurement of people, processes, technologies and assets.
To date ZOOM has helped over 2200 customers and partners worldwide, ranging from sub-100 agent contact centers to brands like Amerigas, IBM, Homecredit, Finansbank, Tata Sky, Generali, Allianz, and Vodafone spanning 90 Countries. More information can be found at zoomint.com or on Twitter @zoomint .
About Elevēo
Elevēo was formed to provide simplified solutions for complex contact center problems. Our products provide only features needed to elevate contact center operations & processes, are built using modern frameworks and cloud native technologies to scale or be hosted anywhere. Elevēo products are birthed from ZOOM International with its rich WFO history, award-winning products, exceptional delivery & reputation for world-class service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005093/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
